MARKET

PLUR

PLUR

PLURILOCK SEC INC
NASDAQ
5.65
+0.04
+0.63%
Closed 14:57 07/26 EDT
OPEN
5.58
PREV CLOSE
5.61
HIGH
5.70
LOW
5.10
VOLUME
3.74K
TURNOVER
0
52 WEEK HIGH
8.48
52 WEEK LOW
3.449
MARKET CAP
30.44M
P/E (TTM)
-1.3418
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLUR last week (0715-0719)?
Weekly Report · 4d ago
Pluri Partners with Kadimastem to Advance Cell Therapy Products for Clinical Trials
Pluri Inc. Has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. To develop therapeutic cells for ALS and diabetes treatments. Pluri will manufacture two cell therapy product candidates for the company. The company leverages its 47,000 square foot cell production facility to manufacture cell-based products for life science companies.
Benzinga · 07/18 06:41
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Leading biotechnology company Pluri Inc. Has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. The company is developing therapeutic cells for ALS and diabetes treatments. PluriCDMO leverages Pluri’s 47,000 square foot cell production facility to manufacture cell-based products.
Barchart · 07/18 01:30
Weekly Report: what happened at PLUR last week (0708-0712)?
Weekly Report · 07/15 10:48
Pluri Announced €1M Proof Of Concept Agreement To Enhance Global Sustainable Vegetable Supply
Pluri Inc. Has announced a strategic proof of concept agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change. Pluri transforms cells into solutions that promote global wellbeing and sustainability.
Benzinga · 07/08 11:06
Weekly Report: what happened at PLUR last week (0701-0705)?
Weekly Report · 07/08 10:49
Pluri Inc. Announces CFO Transition and New Appointment
TipRanks · 07/02 11:01
Weekly Report: what happened at PLUR last week (0624-0628)?
Weekly Report · 07/01 10:50
More
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Webull offers Pluri Inc stock information, including NASDAQ: PLUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLUR stock methods without spending real money on the virtual paper trading platform.